Edwards SAPIEN 3 Transcatheter Heart Valve Receives Approval In China

Tuesday, July 14, 2020

Edwards Lifesciences Corporation today announced that it has received Chinese regulatory approval for the Edwards SAPIEN 3 transcatheter heart valve for the treatment of patients suffering from severe, symptomatic aortic stenosis (AS) at high risk for or unable to undergo open-heart surgery.

“Now, in China, patients diagnosed with severe AS have the option of a shorter procedure with excellent clinical outcomes, including a more rapid recovery than open-heart surgery,” said Prof. Junbo Ge, MD, academician of the Chinese Academy of Sciences, chairman, Shanghai Institute of Cardiovascular Diseases and Director, Department of Cardiology, Zhongshan Hospital, Fudan University.

  • The SAPIEN 3 valve builds on Edwards’ decades of experience in the development of tissue heart valves, and the proven benefits of the Edwards SAPIEN transcatheter heart valves.
  • The SAPIEN TAVR valves are the most widely studied transcatheter valves, with more than 30,000 patients treated in clinical trials and registries in over 65 countries around the world.
  • The approval for high-risk and extreme-risk patients in China was supported by the China SAPIEN 3 study, which complements a highly robust set of clinical outcomes from three randomized controlled PARTNER studies, along with excellent real-world results.

“This approval marks a major milestone for Chinese physicians and their patients living with severe AS in need of alternatives to open-heart surgery,” said Larry L. Wood, Edwards’ corporate vice president, transcatheter aortic valve replacement. “Edwards is proud to introduce this technology, which has demonstrated successful outcomes for patients worldwide, into China. We look forward to partnering with hospitals throughout China to introduce this therapy through our comprehensive, globally proven training program.”

The valve, available in 20mm, 23mm, 26mm and 29mm sizes, is approved by the National Medical Products Administration for treating high-risk patients in China. To date, more than 650,000 patients around the world have benefitted from TAVR.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc.

WE WELCOME YOUR VIEWS

Please enter your comment!
Please enter your name here